Reglan Tardive Dyskinesia Causation: ICD-10 Code and What to Know

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Information to Specific Risk Awareness

The legacy of general health and science information has long provided a foundation for understanding broad physiological principles and disease prevention. Within this framework, public health education traditionally emphasized lifestyle factors, infectious disease control, and the safe use of medications. This general context established baseline awareness of drug side effects, yet often lacked specificity regarding long-term neurological consequences of certain pharmaceutical exposures. As clinical knowledge advanced, the focus narrowed from population-level health guidance to individualized risk assessment, particularly for medications with known cumulative effects. The transition from general health literacy to occupational exposure concern becomes evident when considering the clinical trajectory of patients prescribed Reglan (metoclopramide) for gastrointestinal disorders. While the initial health information context addressed medication benefits and common adverse reactions, the emerging occupational and clinical concern centers on the specific risk of tardive dyskinesia following prolonged Reglan use. This shift requires moving beyond generic health advice to a more targeted evaluation of exposure duration, dosage, and individual susceptibility. The bridge between these domains lies in recognizing that general health information, while valuable, must be supplemented by specialized knowledge of drug-induced movement disorders when assessing patients with extended Reglan exposure histories. This transition underscores the need for precise diagnostic coding and monitoring protocols within clinical and occupational health settings.

Understanding Reglan and Its Link to Tardive Dyskinesia

Reglan (metoclopramide) is a dopamine receptor-blocking agent (DRBA) used primarily for gastrointestinal motility disorders. Its use carries a well-documented risk of causing tardive dyskinesia (TD), a potentially irreversible hyperkinetic movement disorder. The ICD-10 code for neuroleptic-induced tardive dyskinesia is G24.01, which applies to TD caused by any DRBA, including metoclopramide. This section examines the clinical presentation, mechanistic pathways, and risk factors linking Reglan to TD, based on evidence from FDA labeling and peer-reviewed literature. The FDA label for Reglan describes TD as 'a syndrome of potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes of the trunk and/or extremities' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). A case report of a woman with metoclopramide-induced TD notes that her symptoms were initially misjudged as 'functional,' highlighting the diagnostic challenge (https://pubmed.ncbi.nlm.nih.gov/36712453/). Diagnosis is primarily clinical, based on a history of DRBA exposure and the presence of characteristic involuntary movements after ruling out other causes. The condition tends to persist despite dose adjustment or discontinuation of the offending agent (https://pubmed.ncbi.nlm.nih.gov/34703232/).

Pharmacology and Adverse Effects of Reglan

Reglan (metoclopramide) acts as a dopamine D2 receptor antagonist in the central nervous system, which is the mechanism underlying both its therapeutic antiemetic effects and its adverse neurological effects. The FDA boxed warning states: 'Metoclopramide, including Reglan, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The label further notes that the risk of developing TD increases with duration of treatment and total cumulative dosage. Reglan is contraindicated in patients with a history of TD, and the maximum duration of treatment for symptomatic gastroesophageal reflux is 12 weeks. Other extrapyramidal symptoms, such as parkinsonism and dystonia, are also reported, but TD is the most concerning due to its potential irreversibility. The label advises immediate discontinuation of Reglan if signs or symptoms of TD develop.

Mechanistic Pathways Linking Reglan to Tardive Dyskinesia

The pathogenesis of TD involves chronic blockade of dopamine D2 receptors in the striatum, leading to compensatory upregulation of postsynaptic dopamine receptors and altered neurotransmitter signaling. Metoclopramide, as a DRBA, induces these same changes. The condition is described as 'a hyperkinetic movement disorder caused by the use of dopamine receptor-blocking agents (DRBAs), a category of medications that includes first- and second-generation antipsychotics and agents such as metoclopramide' (https://pubmed.ncbi.nlm.nih.gov/34703232/). Although initially associated with typical antipsychotics, the incidence of TD from atypical antipsychotics and antiemetics like metoclopramide is likely similar (https://pubmed.ncbi.nlm.nih.gov/29433808/). Older age is a significant risk factor, with older persons experiencing TD after shorter treatment durations and lower dosages of DRBAs (https://pubmed.ncbi.nlm.nih.gov/34703232/). The condition is often refractory to medication, and treatment options include VMAT2 inhibitors such as tetrabenazine, which have been FDA-approved for TD (https://pubmed.ncbi.nlm.nih.gov/29433808/). In severe cases, pallidal deep brain stimulation has been used, as in the case of a woman with metoclopramide-induced TD who underwent bilateral GPi electrode implantation after 8 years of ineffective medical treatments (https://pubmed.ncbi.nlm.nih.gov/36712453/).

Risk Anchors: Safety Communication and Clinical Interpretation

The FDA has issued a boxed warning for Reglan regarding TD, emphasizing the need for short-term use and periodic reassessment. The warning states: 'Use Reglan for the shortest duration of treatment and periodically reassess the need for continued treatment. Immediately discontinue Reglan in patients who develop signs or symptoms of TD' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with gastroesophageal reflux, the maximum treatment duration is 12 weeks. Clinicians should avoid concomitant use of other drugs known to cause TD and avoid Reglan in patients with Parkinson's disease. The timeline between exposure and TD onset varies; while some patients develop symptoms within months, others may experience delayed onset after years of use. Once TD emerges, it tends to persist, and low rates of remission have contributed to a rising prevalence (https://pubmed.ncbi.nlm.nih.gov/29433808/). Affected patients face increased comorbidities, social stigmatization, and impaired physical and mental health (https://pubmed.ncbi.nlm.nih.gov/34703232/). Causation-focused interpretation requires documenting the temporal relationship between Reglan use and symptom onset, excluding other causes, and recognizing that TD can occur even at low doses in vulnerable populations, particularly older adults.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified medical contexts for case-specific decisions.

Frequently Asked Questions

What is the ICD-10 code for tardive dyskinesia caused by Reglan?

The ICD-10 code for neuroleptic-induced tardive dyskinesia is G24.01. This code applies to tardive dyskinesia caused by any dopamine receptor-blocking agent, including Reglan (metoclopramide).

How does Reglan cause tardive dyskinesia?

Reglan blocks dopamine D2 receptors in the brain. Chronic blockade leads to compensatory upregulation of dopamine receptors and altered signaling, resulting in involuntary movements characteristic of tardive dyskinesia. The risk increases with longer treatment duration and higher cumulative doses.

What are the symptoms of tardive dyskinesia?

Symptoms include involuntary, repetitive movements of the face, tongue, and extremities, such as lip smacking, grimacing, tongue protrusion, and rapid blinking. These movements can be disfiguring and may persist even after stopping Reglan.

Is tardive dyskinesia from Reglan reversible?

Tardive dyskinesia is often irreversible, though symptoms may improve in some cases after discontinuation. The FDA label warns of potentially irreversible movements, and treatment options like VMAT2 inhibitors can help manage symptoms.

Does submitting information create an medical context-client relationship?

No. Submission requests an initial records screening only and does not create an medical context-client relationship.

References

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.